Tien Liang BioTech , Ltd. Overview
Get informed when a big investor buys or sells
+ Follow13.31%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Tien Liang BioTech , Ltd. (4127.TWO) currently reports a ROE of 13.31%. That is above the sector sector average of 11.64%. Use the charts on this page to explore Tien Liang BioTech , Ltd.'s ROE history and peer comparisons.
Tien Liang BioTech , Ltd.'s ROE of 13.31% is higher than the its sector sector average of 11.64%. That is roughly 14.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Tien Liang BioTech , Ltd.'s current 13.31% should be judged against industry norms (sector average: 11.64%) and against 4127.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 13.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Tien Liang BioTech , Ltd., and consider following 4127.TWO for alerts when major investors trade the stock.
